[ad_1]
Molina Healthcare, Inc. (MOH) is a Fortune 500 managed care group headquartered in Lengthy Seashore, California. It operates inside the Well being Companies sector, particularly within the Managed Well being Care trade, and its market capitalization stands at $9.5 billion.
Molina Healthcare delivers important medical health insurance providers by government-funded packages, together with Medicaid, Medicare, and state Market choices primarily focusing on low-income and underserved populations throughout a number of U.S. states.
On a year-to-date (YTD) foundation, Molina Healthcare inventory has considerably underperformed, with its inventory declining 39.5%, whereas the broader S&P 500 Index ($SPX) has gained 10.2%. Over the previous 52 weeks, MOH has slipped 49.7%, whereas the benchmark rose 15.2% over the identical stretch.
Narrowing the main focus, MOH inventory has additionally trailed behind the SPDR S&P Well being Care Companies ETF (XHS), which tracks the healthcare providers sector. XHS rose 9% in 2025, whereas remaining flat with round 0.1% beneficial properties over the previous yr.
MOH inventory’s latest decline stems largely from intensifying medical price pressures throughout its core government-backed medical health insurance segments, together with Medicaid, Medicare, and ACA Market plans. These elevated prices have outpaced premium income will increase, diminishing profitability and triggering a downward revision of full-year adjusted EPS steerage to at the very least $19.
Within the Q2 2025 earnings report, launched on July 23 after the bell, Molina Healthcare generated income of $11.4 billion, up 15.7% year-over-year (YoY). Nonetheless, adjusted EPS got here in at $5.48, down 6.5% yearly. MOH inventory slipped almost 17% within the subsequent buying and selling session.
For the present fiscal yr, ending in December 2025, analysts anticipate Molina’s EPS to say no 18.1% YoY to $18.56, on a diluted foundation. The corporate has a blended earnings shock historical past total. Whereas it surpassed the Road’s bottom-line projections in two of the trailing 4 quarters, it missed the EPS estimates within the different two.
Total, Wall Road seems cautious about MOH inventory, with a consensus “Maintain” ranking – a downgrade from a “Average Purchase” ranking. Of the 17 analysts at present providing suggestions, 4 advise a “Robust Purchase,” 11 give a “Maintain,” one has a “Average Promote” ranking, and the remaining one has a “Robust Promote” ranking.
[ad_2]
